GFAP and Alzheimer disease: In summary, we speculate that functionalchanges (i.e., EAAT2 lossand decreased glutamate uptake capacity) may precede astrocytic morphologicalalterations (e.g., GFAP increased levels) and deposition of insolubleAβ aggregates in the early stages of AD.